Loading, Please Wait...
MONTREAL, May 15, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) today held its annual meeting of shareholders.
As part of the meeting, shareholders proceeded to elect the Company’s Board of Directors for a one-year term and elected KPMG LLP, as auditors for the current fiscal year. In addition, shareholders approved the renewal of the shareholder rights plan.
All candidates proposed for the position of directors were elected in the following proportion:
|Sheila M. Frame||26,327,013||99.53||123,849||0.47|
|Gérald A. Lacoste||26,001,144||98.30||449,718||1.70|
In addition to reviewing highlights from last year, both Ms. Svoronos and Mr. Luc Tanguay, respectively Chair of the Board and President and CEO of Theratechnologies, addressed people present at the meeting.
“At the same time last year, I said that Theratechnologies was entering a new era. A year later, the numbers speak for themselves. In fact, this is only the beginning and the Board is completely supportive of the plan being methodically implemented by Management. Theratechnologies has been on the path of success and growth for several years now and the future looks even brighter,” said Dawn Svoronos, Chair of the Board, Theratechnologies Inc.
“Given how the Company is evolving, we are now actively assessing a listing on NASDAQ. Furthermore, in a few weeks from now, we should be in a position to share our strategic plan for NAFLD/NASH,” said Luc Tanguay, President and CEO, Theratechnologies Inc.
“A year into the launch of Trogarzo® in the United States, we strongly believe that we are on track to generate sales of at least five times those of EGRIFTA® in the coming years. This is not even taking into account the potential contribution of Europe where we are awaiting the recommendation from the CHMP,” added Luc Tanguay.
“While revenues keep growing strongly, our goal is also to give the Company a longer term horizon. This is one of the arguments behind the acquisition of a unique platform in oncology which has already shown promising results in pre-clinical trials,” concluded Mr. Tanguay.
Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including those living with HIV. Further information about Theratechnologies is available on the Company's website at www.theratech.com and on SEDAR at www.sedar.com.
This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management’s beliefs and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as "may", "will", "should", "could", “would”, "outlook", "believe", "plan", "envisage", "anticipate", "expect" and "estimate", or the negatives of these terms, or variations of them. The forward-looking statements contained in this press release include, but are not limited to statements regarding the long-term growth of the Company, the amount of sales to be generated from Trogarzo® and the issuance of a positive opinion on Trogarzo® by the CHMP.
Forward-looking statements are based upon a number of assumptions and include, but are not limited to, the following: sales of EGRIFTA® and Trogarzo® will continue to increase, our expenses will not increase significantly, Trogarzo® will be approved for commercialization in Europe and the results of research and development work on the oncology platform will be positive.
Forward-looking statements are subject to a variety of risks and uncertainties, many of which are beyond our control that could cause our actual results to differ materially from those that are disclosed in or implied by the forward-looking statements contained in this press release. These risks and uncertainties include, among others, the risk that the sales of our products remain stable or decreases, Trogarzo® is not approved for commercialization in Europe, or as a condition precedent to approval, additional clinical trials need to be conducted, and results from research and development works carried out on our oncology platform are negative.
We refer potential investors to the "Risk Factors" section of our annual information form dated February 20, 2019 for additional risks regarding the conduct of our business and Theratechnologies. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date.
We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.
Vice President, Communications and Corporate Affairs